Oral Immune-Related Adverse Events - Current Concepts and their Management

被引：3

作者：

Asan, Mohamed Faizal ^{[1
]}

Castelino, Renita Lorina ^{[1
]}

Babu, Subhas G. ^{[1
]}

Rao, Kumuda ^{[1
]}

Pandita, Vaibhav ^{[1
]}

机构：

[1] Nitte Deemed be Univ, AB Shetty Mem Inst Dent Sci, Dept Oral Med & Radiol, Mangalore, Karnataka, India

来源：

ASIA-PACIFIC JOURNAL OF ONCOLOGY NURSING | 2021年 / 8卷 / 06期

基金：

英国科研创新办公室;

关键词：

Immune-related adverse events; immunotherapy; oral mucositis; quality of life; LEVEL LASER THERAPY; CHECKPOINT INHIBITORS; LICHENOID REACTIONS; CANCER; ANTI-PD-1; SAFETY; PEMBROLIZUMAB; IMMUNOTHERAPY; IPILIMUMAB; NIVOLUMAB;

D O I：

10.4103/apjon.apjon-2136

中图分类号：

R47 [护理学];

学科分类号：

1011 ;

摘要：

Recent advent of immune checkpoint inhibitors (ICIs) have made significant improvement in the treatment outcome of cancer patients. They are also known to increase the overall survival in many malignancies. They target key immune checkpoints, acting on the cytotoxic T-lymphocyte antigen-4, programmed death-1 (PD-1), and PD-1 ligand 1 pathways. ICIs are effective in cancer therapy, but also possess various adverse effects that are termed together as immune-related adverse events (irAEs). Information focusing only on the oral reactions of irAEs is scanty in the literature. Therefore, we performed a computerized database search in PubMed and Google Scholar to identify and collect data regarding the oral adverse effects of ICIs. The early recognition of oral irAEs and appropriative intervention may help in improving the quality of life in patients. This paper presents a brief review of oral irAEs and their management.

引用

页码：604 / 609

页数：6

共 50 条

[1] Long-term survival of a randomized phase III trial of head and neck cancer patients receiving concurrent chemoradiation therapy with or without low-level laser therapy (LLLT) to prevent oral mucositis [J].

Antunes, Heliton S. ;

Herchenhorn, Daniel ;

Small, Isabele A. ;

Araujo, Carlos M. M. ;

Pais Viegas, Celia Maria ;

Ramos, Gabriela de Assis ;

Dias, Fernando L. ;

Ferreira, Carlos G. .

ORAL ONCOLOGY, 2017, 71 :11-15

[2] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[3] The pathogenesis of mucositis: updated perspectives and emerging targets [J].

Bowen, J. ;

Al-Dasooqi, N. ;

Bossi, P. ;

Wardill, H. ;

van Sebille, Y. ;

Al-Azri, A. ;

Bateman, E. ;

Correa, M. E. ;

Raber-Durlacher, J. ;

Kandwal, A. ;

Mayo, B. ;

Nair, R. G. ;

Stringer, A. ;

ten Bohmer, K. ;

Thorpe, D. ;

Lalla, R. V. ;

Sonis, S. ;

Cheng, K. ;

Elad, S. .

SUPPORTIVE CARE IN CANCER, 2019, 27 (10) :4023-4033

[4] Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline [J].

Brahmer, Julie R. ;

Lacchetti, Christina ;

Schneider, Bryan J. ;

Atkins, Michael B. ;

Brassil, Kelly J. ;

Caterino, Jeffrey M. ;

Chau, Ian ;

Ernstoff, Marc S. ;

Gardner, Jennifer M. ;

Ginex, Pamela ;

Hallmeyer, Sigrun ;

Chakrabarty, Jennifer Holter ;

Leighl, Natasha B. ;

Mammen, Jennifer S. ;

McDermott, David F. ;

Naing, Aung ;

Nastoupil, Loretta J. ;

Phillips, Tanyanika ;

Porter, Laura D. ;

Puzanov, Igor ;

Reichner, Cristina A. ;

Santomasso, Bianca D. ;

Seigel, Carole ;

Spira, Alexander ;

Suarez-Almazor, Maria E. ;

Wang, Yinghong ;

Weber, Jeffrey S. ;

Wolchok, Jedd D. ;

Thompson, John A. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) :1714-+

[5] Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab [J].

Brand, Fanny Zulay Acero ;

Suter, Nicolas ;

Adam, Jean-Philippe ;

Faulques, Bernard ;

Maietta, Antonio ;

Soulieres, Denis ;

Blais, Normand .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6

[6] Incidence of and risk factors for development of oral mucositis in outpatients undergoing cancer chemotherapy [J].

Cakmak, Seher ;

Nural, Nesrin .

INTERNATIONAL JOURNAL OF NURSING PRACTICE, 2019, 25 (01)

[7]

Cecchi C, CLIN LUNG CANCER, V2021

[8] Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors [J].

Choi, Juwhan ;

Lee, Sung Yong .

IMMUNE NETWORK, 2020, 20 (01)

[9] Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls [J].

Darnell, Eli P. ;

Mooradian, Meghan J. ;

Baruch, Erez N. ;

Yilmaz, Melis ;

Reynolds, Kerry L. .

CURRENT ONCOLOGY REPORTS, 2020, 22 (04)

[10] Prevention and Treatment of Chemotherapy and Radiotherapy Induced Oral Mucositis [J].

Daugelaite, Goda ;

Uzkuraityte, Kriste ;

Jagelaviciene, Egle ;

Filipauskas, Aleksas .

MEDICINA-LITHUANIA, 2019, 55 (02)

← 1 2 3 4 5 →